Loading

Commentary Open Access
Volume 1 | Issue 1 | DOI: https://doi.org/10.46439/immunol.1.007

DNA hyper methylation editing of T cell receptor signaling and the fellow molecules: a promise strategy of predicting acquired immune checkpoint inhibitors (ICIs) resistance

  • 1Department of Oncology, China-Japan Friendship Hospital, Yinghuayuan East Street 2 China-Japan Friendship hospital, Chaoyang, Beijing, China
  • 2Beijing University of Chinese Medicine, No.11, 3rd Ring Road East Beijing University of Chinese Medicine, Chaoyang, Beijing, China
+ Affiliations - Affiliations

Corresponding Author

Huijuan Cui, cuihj1963@sina.com

Received Date: August 14, 2022

Accepted Date: August 22, 2022

Abstract

The promising results of immune checkpoint inhibitors (ICIs) in tumors have changed the current treatment modality for cancer. ICIs response prediction is urgently needed for the personalized therapy approach. In the recent issue of the Journal of Oncology, Zixin Hu et al. proposed that DNA methylation alternations contribute to tumor microenvironment (TME) reshapement to predict the ICIs response. Notwithstanding the global DNA methylation loss, the repression of T cell receptor signaling and the fellow costimulators by DNA hypermethylation contributed to the cold TME and ICIs resistance. Hub immune-associated genes edited by DNA methylation also bonded the driver genes and TME. DNA methylation is a promise predictive biomarker and DNA methylation inhibitors may be a novel strategy to fuel ICIs.

Keywords

DNA methylation, Immune checkpoints inhibitors, Biomarker, T cell receptor, Tumor microenvironment

Author Information X